QR Code

Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

The widely used chemotherapy cisplatin causes permanent hearing loss in 40%–60% of patients with cancer. One drug, sodium thiosulfate, is approved by the FDA for use in pediatric patients with localized solid tumors for preventing cisplatin-induced hearing loss, but more drugs are desperately needed...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Matthew A. Ingersoll, Richard D. Lutze, Chithra K. Pushpan, Regina G. Kelmann, Huizhan Liu, Mark T. May, William J. Hunter, David Z.Z. He, Tal Teitz
Hōputu: Artigo
Reo:Inglês
I whakaputaina: American Society for Clinical investigation 2023-12-01
Rangatū:JCI Insight
Ngā marau:
Otology
Therapeutics
Urunga tuihono:https://doi.org/10.1172/jci.insight.171140
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite